

PART I

STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2013

Particulars	Stand alone			Consolidated		
	Three months ended		Year Ended	Three months ended		Year Ended
	30.06.2013	31.03.2013	31.03.2013	30.06.2013	31.03.2013	31.03.2013
	Unaudited	Audited (Refer note 8)	Unaudited	Audited	Unaudited (Refer note 8)	Audited
1 Income from operations						
(a) Net sales/Income from operations (Net of excise duty)	159,578	145,524	111,256	535,291	169,960	155,268
(b) Other operating income	1,596	1,769	1,697	7,219	1,596	1,769
Total income from operations (net)	161,174	147,293	112,953	542,510	171,556	157,037
2 Expenses						
(a) Cost of material consumed	79,559	73,222	66,172	305,364	78,693	75,580
(b) Purchase of stock-in-trade	1,884	1,671	2,407	7,809	5,173	5,502
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	5,658	5,397	(5,948)	(12,108)	5,262	(615)
(d) Employee benefits expense	12,346	11,127	10,212	43,142	18,891	17,518
(e) Depreciation and amortisation expense	4,593	4,598	4,104	17,139	7,192	6,928
(f) Provision for decline in the value of long-term investment	-	5,100	-	6,900	-	-
(g) Other expenses	24,901	25,479	21,574	95,597	32,766	35,044
Total expenses	128,941	126,594	98,521	463,843	147,977	139,957
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	32,233	20,700	14,432	78,667	23,579	17,080
4 Other income	287	663	108	1,501	392	1,409
5 Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)	32,520	21,363	14,540	80,168	23,971	18,489
6 Finance costs (refer note 6)	2,073	2,595	3,030	11,474	2,539	3,160
7 Foreign exchange (Gain)/Loss (refer note 6)	13,953	(954)	19,325	12,382	17,241	130
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	16,494	19,722	(7,815)	56,312	4,191	15,199
9 Exceptional item	-	-	-	-	-	-
10 Profit/(Loss) from ordinary activities before tax (8-9)	16,494	19,722	(7,815)	56,312	4,191	15,199
11 Tax expense/(credit)	2,131	3,368	(2,831)	6,713	2,445	4,452
12 Net Profit/(Loss) for the period (10-11)	14,363	16,354	(4,984)	49,599	1,746	10,747
13 Minority interest	-	-	-	-	(114)	(114)
14 Net Profit/(Loss) after taxes and minority interest (12-13)	14,363	16,354	(4,984)	49,599	1,860	10,861
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	2,912	2,912	2,911	2,912	-	-
16 Reserves excluding Revaluation Reserve	-	-	-	290,998	-	-
17 Earnings per share of Re.1/- each (not annualised)						
(a) Basic	4.93	5.62	(1.71)	17.04	0.64	3.73
(a) Diluted	4.93	5.61	(1.71)	17.02	0.64	3.73



PART II

SELECT INFORMATION FOR THE QUARTER ENDED 30.06.2013

Particulars	Three months ended			Year Ended
	30.06.2013	31.03.2013	30.06.2012	31.03.2013
A				
1 PARTICULARS OF SHAREHOLDING				
Public Shareholding	131,514,694	131,514,844	131,708,307	131,514,844
- Number of Shares	45.16	45.16	45.24	45.16
- Percentage of Shareholding				
2 Promoters and promoter group Shareholding				
a) Pledged/Encumbered	30,005,297	37,461,297	36,686,605	37,461,297
- Number of Shares	18.79	23.46	23.01	23.46
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	10.30	12.86	12.60	12.86
- Percentage of Shares (as a % of the total share capital of the company)				
b) Non-encumbered	129,691,299	122,235,149	122,726,378	122,235,149
- Number of Shares	81.21	76.54	76.99	76.54
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	44.54	41.97	42.16	41.97
- Percentage of Shares (as a % of the total share capital of the company)				

Particulars	Three months ended 30.06.2013
B	
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	1
Received during the quarter	57
Disposed of during the quarter	58
Remaining unresolved at the end of the quarter	Nil



NOTES:

- 1 The above unaudited financial results as reviewed by the Audit Committee have been approved by the Board at its meeting held on August 9, 2013. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- 2 The consolidated audited financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Ventures.
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 Sales of standalone for the current quarter include exports Rs. 126,586 lakhs (Quarter ended June 30, 2012: Rs. 81,074 lakhs).
- 5 Net sales for the current quarter include dossier income in standalone of Rs. 238 lakhs (June 30, 2012: Rs. 366 lakhs) and in consolidated of Rs. 298 lakhs (June 30, 2012: Rs. 679 lakhs).
- 6 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs. 5,048 lakhs, Rs. 4,776 lakhs, Rs. Nil and Rs. 13,532 lakhs for three months ended June 30, 2013, June 30, 2012, March 31, 2013 and for the year ended March 31, 2013 respectively, arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- 7 With effect from April 1, 2013, the Company has changed the accounting policy for valuation of cost of the inventory from 'first-in -first out' basis to 'moving average basis'. Accordingly, this has resulted into decrease in the value of inventory on standalone basis and consolidated basis as at June 30, 2013 by Rs. 60 lakhs and Rs. 158 lakhs respectively and decrease in profit before tax on standalone basis and consolidated basis of the quarter ended June 30, 2013 by Rs. 60 lakhs and Rs. 44 lakhs respectively.
- 8 The figures of the quarter ended March 31, 2013 are the balancing figures between audited figures in respect of the full financial year ended March 31st and unaudited published year to date figures upto the third quarter ended December 31st. The unaudited consolidated results published year to date figures upto the third quarter ended December 31st were not subject to limited review and the unaudited standalone results were subject to limited review.
- 9 Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N. Govindarajan
Managing Director



Place: Hyderabad
Date: August 9, 2013

www.aurobindo.com

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

Oval Office, 18, iLabs Centre
Hitech City, Madhapur
Hyderabad-500 081, India

Tel : +91 40 6736 2000

Fax : +91 40 6736 2200

Limited Review Report

To
**Board of Directors of
Aurobindo Pharma Limited,**

1. We have reviewed the accompanying statement of unaudited unconsolidated financial results of Aurobindo Pharma Limited ("the Company") for the quarter ended June 30, 2013, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement of unaudited unconsolidated financial results of the Company based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements ('SRE') 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement(s). A review is limited primarily to enquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited unconsolidated financial results prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006, (as amended) as per Section 211(3C) of the Companies Act, 1956, and other accounting principles generally accepted in India; has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W



per Vikas Kumar Pansari

Partner

Membership No.: 093649



Place: Hyderabad

Date:

9/8/2013